Abstract: Objective: To systematically retrieve, evaluate, and summarize the available evidence related to breast cancer risk management for BRCA1/2 mutation female carriers from both domestic and international sources, so as to inform evidence-based practice. Methods: A systematic search was conducted on relevant guidelines and expert consensuses published on websites of organizations and several databases from September 1, 2018 to September 1, 2023. Four researchers independently assessed the quality of included guidelines and expert consensuses, extracted and summarized the evidence. Results: A total of 8 guidelines and 6 expert consensuses were included, with 4 from domestic sources and 10 from international sources. According to the overall quality assessment of guidelines included, two guidelines were assessed as Grade A and 6 Grade B. All expert consensuses were enrolled after quality assessment. There were 20 pieces of best evidence including 4 aspects summarized, namely risk identification and assessment, risk monitoring, risk control and intervention, education and raising awareness. Conclusion: The best evidence for breast cancer risk management in BRCA1/2 mutation female carriers could provide references for healthcare professionals in developing management strategies and conducting clinical practices. However, the best evidence should be selected according to the clinical situations and patients' preferences.

Key words: BRCA1; BRCA2; breast cancer; risk management; evidence summary; evidence-based nursing